The record

LegislationLegislation· Sep 2024
HR 3884

Sponsored by Michael C. Burgess (R)

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Would have extended the Sickle Cell Disease Treatment Demonstration Program through , the 2028 federal budget year.

Tradeoff

Would have raised the program's yearly funding to $8,205,000 for 2024 through 2028. Sickle cell disease causes pain, anemia, infections, and stroke, and the program aims to improve its treatment and prevention.

What's in it

See official bill text
H.R. 3884, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023www.cbo.gov/publication/59857 · Jan 2024

The House passed this bill by on September 23, 2024. The Senate never voted on it before the Congress ended, so the bill expired.

  1. House

    Introduced

    (Jun 7, 2023)

  2. House

    Committee on Energy and Commerce(Jun 7, 2023)

  3. House

    The Committee on Energy and Commerce voted to send it to the floor

    Reported 50 - 0(Jul 19, 2023)

    Committee report H. Rept. 118-166.

  4. House

    Passage of the bill

    Passed by (Sep 23, 2024)

    No individual votes were recorded.

  5. Senate

    Received from the House

    on Health, Education, Labor, and Pensions(Sep 24, 2024)